EORTC radiation oncology group

-$1

Keynote Lecture - Survey Groups

Thursday, February 22, 2007 Keynote Lecture

Nrof

Nrof

patients

patients

required

ioduded

(1-11-2006)

344

278

Ongoing

J.A.Langendijk 350

104

Ongoing

StudyCoordiStudy

Design

Subject

nator

1 speaker Roleof ARCON

DIFFERENTIAL SURVIVAL OF H&N CANCER PATIENTSIN EUROPE

ARCON

Phase III

F.Berrino Istituto Nazionale dei Tumori, Milan, Italy

Roleof reduction overall

(highrisk)

Phaselll

treatment time in postup.

setting

2 speaker

Roleof reduc-

tion overall

PARI'IR

DAHANCA

(intennedi-

J. Overgaard

ate risk)

PhaseIII

treatment

CJ.Terhaard

360

12

Ongoing

CR.Rasch

240

240

Closed

R.de Bree

160

50

Ongoing

time in postup. setting

Aarhus University Hospital, Dept. of Experimental and Clinical OncoIogy, Aarhus, Denmark 3speaker

J.R.A.M, I(aanders

cancer

POPART

Head and NeckEuropeanCooperativeGroups:Surveyand Presentationot the OngoingResearch

in laryngeal

Status

Roleif

RADPLAT

PhaseIII

intra-arterial chemoradiation

GORTEC

J. Bourhis(Franc~

Roleof PET

RELAPS

PhaseIII

in recurrent laryngealca

4speaker EORTC H&N GROUP

J. Vermorken (Belgium) 5 speaker EORTC RADIATION ONCOLOGY GROUP

K. Haustermans (Belgium) 6speaker THE DUTCH HEAD AND NECK CANCER COOPERATIVE STUDY GROUP (NWHHT-SG) J. Langendijk ON BEHALFOFTHENWHHT-SG Introduction: The NWHHT-SGwas founded in 2004 as a subcommittee of the NWHHT. The main objectives of the Study Group were to serve as a platform for new study proposals, to activate multicenter clinical studies and to inform the members of the Group about ongoing studies in the field of head and neck cancer. Since then, the study-coordinators of ongoing studies regularly reported on the status of their studies and, moreover, a number of new studies were initiated. In this presentation, these studies will be briefly reviewed. Summary of ongoing studies:

In these 5 studies, a total number of 684 patients have been included upto November 2006. Conclusion: Although the NWHHT-SG started just in 2004, a number of clinical studies were initiated and some of them will be succesfully closed in the near future. The ongoing studies will be discussed briefly. 7 speaker ARO S. Staar (Germany)

8 speaker PRELIMINARY RESULTSFROM A SWEDISH STUDY OF CONVENTIONAL VERSUS ACCELERATEDFRACTIONATED OF SQUAMOUS CARCINOMA OFTHE HEAD AND NECK (ARTSCAN) B. Zackrisson ~, E. Kjell~n 2,T. Bj6rk-Eriksson 3, S. Friesland 4, J. Reizenstein ~, M. Lagerlund6, L. Ekberg 7, B. L6d~nn,J. Ahlgren 9, G. Adell 1°, K. Bj6rnlinger ~, K.A. Johansson 12 7UMEA UNIVERSITYHOSPITAL,Department of Oncology, Umea, Sweden, 2LUND UNIVERSITYHOSPITAL, Lurid, Sweden, 3SAHLGRENSKAUNIVERSITYHOSPITAL, Gdteborg, Sweden, 4KAROLINSKA UNIVERSITYHOSPITALAT SOLNA,

Stockholm, Sweden,

SC)REBROUNIVERSITYHOSPITAL, Orebro,Sweden, 6KAROLINSKA UNIVERSITYHOSPITALAT HUDDINGE, Stockholm,Sweden, 7UNIVERSITY HOSPITAL MALMO,

Maim6, Sweden,

8CENTRAL HOSPITAL, Karlstad, Sweden,

9G~.VLECOUNTYHOSPITAL,G6vle,Sweden, ~OLINKOP~NGUNIVERS~TYHOSPITAL,LinkSping, Sweden, "RYHoVCOUNTYHOSPITAL,J6nk6ping, Sweden, ~2SAHLGRENSKAUNIVERSITYHOSPITAL,Department of Radiation Physics,

G6teborg, Sweden Background: Fractionation in radiotherapy has been the object for randomised clinical studies. Some studies of accelerated fractionation (AF) have shown increased efficacy in treatment of head and neck cancers while others have not. Many studies are small and the number of patients too small to draw conclusion on severe late side effects from. 1998 a national Swedish group decided to perform a randomised controlled clinical study of AF. The study was called